Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174282
Title: | European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain |
Author: | Caldas, María Pérez Aisa, Ángeles Castro Fernández, Manuel Bujanda, Luis Lucendo, Alfredo Rodrigo, Luis Huguet, Jose Pérez Lasala, Jorge Molina Infante, Javier Barrio, Jesús Fernández Salazar, Luis Lanas, Ángel Perona, Mónica Domínguez Cajal, Manuel Ortuño, Juan Gómez Rodríguez, Blas Almela, Pedro Botargués, Josep María Núñez, Óscar Modolell, Inés Gómez, Judith Ruiz Zorrilla, Rafael Coba, Cristóbal De La Huerta, Alain Iyo, Eduardo Pozzati, Liliana Antón, Rosario Barenys de Lacha, Mercé Angueira, Teresa Fernández Bermejo, Miguel Campillo, Ana Alcedo, Javier Pajares Villarroya, Ramón Mego, Marianela Bermejo, Fernando Domínguez Jiménez, José Titó, Llúcia Fernández, Nuria Pabón Carrasco, Manuel Cosme, Ángel Mata Romero, Pilar Alcaide, Noelia Ariño, Inés Maira, Tommaso Di Garre, Ana Puig, Ignasi Nyssen, Olga Megraud, Francis O’Morain, Colm Gisbert, Javier |
Keywords: | Infeccions per Helicobacter pylori Terapèutica Helicobacter pylori infections Therapeutics |
Issue Date: | 25-Dec-2020 |
Publisher: | MDPI |
Abstract: | The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/antibiotics10010013 |
It is part of: | Antibiotics, 2020, vol. 10, num. 1 |
URI: | http://hdl.handle.net/2445/174282 |
Related resource: | https://doi.org/10.3390/antibiotics10010013 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
antibiotics-10-00013-v2.pdf | 909.61 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License